An aggressive bone marrow evaluation including immunocytology with GD2 for advanced retinoblastoma

Journal of Pediatric Hematology/Oncology

Volumn 28, Issue 6, 2006, Pages 369-373

  Chantada, Guillermo L ^a   Rossi, Jorge ^a   Casco, Fernando ^a   Fandiño, Adriana ^a   Scopinaro, Marcelo ^a   De Dávila, María T G ^a   Abramson, David H ^b  

^a HOSPITAL DE PEDIATRÍA PROF DR JUAN P GARRAHAN   (Argentina)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Bone marrow biopsy; GD2; Immunocytology; Metastasis; Retinoblastoma

Indexed keywords

ANTIBODY; ANTINEOPLASTIC AGENT; GANGLIOSIDE GD2;

ADVANCED CANCER; ARTICLE; BONE MARROW BIOPSY; BONE MARROW METASTASIS; CANCER SURVIVAL; CYTOLOGY; FEMALE; HUMAN; ILIAC CREST; IMMUNOFLUORESCENCE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RETINOBLASTOMA; RISK FACTOR;

BIOPSY; BONE MARROW; BONE MARROW EXAMINATION; BONE MARROW NEOPLASMS; GANGLIOSIDES; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MONITORING, PHYSIOLOGIC; NEOPLASM STAGING; NEOPLASM, RESIDUAL; RETINAL NEOPLASMS; RETINOBLASTOMA; RETROSPECTIVE STUDIES; RISK FACTORS;

EID: 33745662910     PISSN: 10774114     EISSN: 15363678     Source Type: Journal    
DOI: 10.1097/00043426-200606000-00009     Document Type: Article

References (18)

1. Mc Kay CJ, Abramson DH, Ellsworth BM. Metastatic patterns of retinoblastoma. Arch Ophthalmol. 1984;102:391-396.
2. Brodeur G, Seeger RC, Barrett A, et al. International Criteria for diagnosis, staging, and response to treatment in patients with neuroblastoma. J Clin Oncol. 1988;6:1874-1881.
3. Oberlin O, Bayle C, Hartmann O, et al. Incidence of bone marrow involvement in Ewing's sarcoma: value of extensive investigation of the bone marrow. Med Pediatr Oncol. 1995;24:343-346.
4. Zacharoulis S, Abramson DH, Dunkel IJ. More aggressive bone marrow screening in retinoblastoma patients is not indicated. The Memorial Sloan Kettering Cancer Center experience. Pediatr Blood Cancer. 2005. In press.
5. Pratt C, Meyer D, Chenaille P, et al. The use of bone marrow aspirations and lumbar punctures at the time of diagnosis of retinoblastoma. J Clin Oncol. 1989;7:140-143.
6. Mohney BG, Robertson DM. Ancillary testing for metastasis in patients with newly diagnosed retinoblastoma. Am J Ophthalmol. 1994;118:707-711.
7. Azar D, Donaldson C, Dalla-Pozza L. Questioning the need for routine bone marrow aspiration and lumbar puncture in patients with retinoblastoma. Clin Experiment Ophthalmol. 2003;31:57-60.
8. Cheung NK, Heller G, Kushner B, et al. Detection of metastatic neuroblastoma in bone marrow: when is routine bone marrow histology insensitive? J Clin Oncol. 1997;15:2807-2817.
9. Valentine L, Moss T, Olson E, et al. Shed tumor gangliosides and progression of human neuroblastoma. Blood. 1990;75:1564-1567.
10. Saarinen UM, Sariola H, Hovi L. Recurrent disseminated retinoblastoma treated by high-dose chemotherapy, total body irradiation, and autologous bone marrow rescue. Am J Pediatr Hematol Oncol. 1991;13:315-319.
11. Grabowski E, Abramson D. Intraocular and extraocular retinoblastoma. Hematol Oncol Clin North Am. 1987;1:721-735.
12. Dunkel IJ, Chantada GL, Fandiño AC, et al. Lack of activity of oral etoposide for relapsed intraocular retinoblastoma. Ophthalmic Genet. 2004;25:25-29.
13. Chantada GL, Dunkel IJ, de Davila MTG, et al. Retinoblastoma patients with high risk ocular pathological features: who needs adjuvant therapy? Br J Ophthalmol. 2004;88:1069-1073.
14. Abramson DH, Frank C, Chantada GL et al. Intraocular carboplatin concentrations following intravenous administration for human intraocular retinoblastoma. Ophthalmic Genet. 1999;20:31-36.
15. Bellaton E, Bertozzi A, Behar C, et al. Neoadjuvant chemotherapy for extensive unilateral retinoblastoma. Br J Ophthalmol. 2003;87:327-329.
16. Dunkel IJ, Aledo A, Kernan NA, et al. Successful treatment of metastatic retinoblastoma. Cancer. 2000;89:2117-2121.
17. Portoukalian J, David MJ, Gain P, et al. Shedding of GD2 ganglioside in patients with retinoblastoma. Int J Cancer. 1993;53:948-951.
18. Cheung IY, Lo Piccolo MS, Kushner BH, et al. Quantitation of GD2 synthase mRNA by real-time reverse transcriptase polymerase chain reaction: clinical utility in evaluating adjuvant therapy in neuroblastoma. J Clin Oncol. 2003;15:1087-1093.